1.LevyGA.Neoral therapy in liver transplantation .Transplant Proc,1996,28:2225
2.SchroederTJ First MR,Mansour ME et al .Antimurine antibody formation following OKT3THERAPY.Transplantation,1990,49:48
3.HoodKA,Zarembski DG.Mycophenolate mofetil: a uniqueimmunosupprewwive agent.AmHealth Syst Pharm,1997,54(3):285
4.McDiarmid SVwww.gydjdsj.org.cn/sanji/.Mycophenolate mofetil in liver transplantation.ClinTransplant,1996,10(1 Pt 2):140
5. Klupp J,Bechstein WO,Platz KP etal .Mycophenolate mofetil added to immunosuppression after livertransplantation-first results.Transpl Int,1997,10(3):223
6. McDiarmid SV,Busuttil RW,AscherNL. et al .FK506(tacrolimus) compared with cyclosporine for primaryimmnosuppression after pediatric liver transplantation:Result from the USmulticenter trial .Transplantation,1995,59:530
7. Platz KP,Muelleer AR,Jonas S etal .Toxicity versus rejection or why conversions between cyclosporine A andFK506 were performed after liver transplantation.Clin Transplant,1995,9:146
8. Wall WJ,Ghent CN,Roy A et al.Useof OKT3 monoclonal antibody as induction therapy for control of rejection inliver transplantation.Pig Dis Sci,1995,40:52
9. Portela D,Patel R,Larson-kellerJJ et al .OKT3 treatment for allograft rejection is a risk factor forcytomegalovirus disease in liver transplantation.J Infect Dis,1995,171:1014
10.Winston DJ,Imagaws DH,Holt CD et al .Long-term ganwww.gydjdsj.org.cn/shouyi/cylovir prophylaxiseliminates serious cytomegalovirus disease in liver transplantation recipientsreceiving OKT3 therapy for rejection.Transplantation,1995,60:1357
11. LegmannP ,Dousset B,Tudoret L et al .Hyperacute rejection in liver transplantation :CTfindings,J Comput Assist Tomogr,1994,18:139
12.Abraham SC Furth EE Receiver operating characteristic analysis of serumchemical parameters as tests of liver transplant rejection and correlation wityhistology.Transplantation,1995,59:740
13.Umeshita K,Monder M,Tono T et al .Determination of the presence ofinterleukin-6 in bile after orthotopic liver transplantation Its role in thediagnosis of acute rejection.Ann Surg,1996,223:204
14. LangT,Krams SM,Villanueva JC et al .Differential patterns of circulatingintercellular adhesion molecule-1(Cicam-1) and vascular cell adhesionmolecule-1(Cvcam-1)during liver allograft rejction.Transplantation,1995,59:584
15.Bijleveld CG,Klompmaker IJ,Vandenberg AP et al .Incidence ,risk factors,andoutcome of antithymocyte globulin treatment of steroid-resistant rejectionafter liver transplantation.Transpl Int,1996,9:570
16.McDiarmid SV,Wallace P,Vargas J et al.The treatment of intractable rejectionwith tacrolimus (FK506) in pediatric liver transplant recipients,j PediatrGastroenterol Nurr,1995,20:291
17. PlatzKP,Mueller AR,Zytowski M et al .Management of acute steroid-resistant rejetionafter liver transplantation .World Surg,1996,20:1052
18.Jindal RM,Pescovitz MD,Cummings OW et al .Persistence of cyclosporine afterwithdrawal of the drug in a patient with chronic liver transplant rejection.Role of themonoethylglycinexylidine test.Transplantation.199,61:1657
